DelveInsight's "Acute Ocular Pain Market Insights, Epidemiology, and Market Forecast 2030" reports deliver an in-depth understanding of the disease, historical and forecasted epidemiology, the pipeline insight as well as the Acute Ocular Pain market size and shares analysis in the seven major markets (7MM) (i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.
The report also covers emerging drugs, current treatment practices, Acute Ocular Pain market shares of the individual therapies, a detailed current Acute Ocular Pain treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities and assesses the underlying potential of the market.
Acute Ocular Pain Market Key Facts
- As per the study by Dana et al. (2019), the annual incidence rates of dry eye disease in the overall population ranged between 0.55% and 0.87%, with an increasing trend over time. The incidence of dry eye disease was consistently higher among females (2008-2012: 0.81-1.21%) than males.
- It is observed that Dry eye disease and ocular neuropathic pain (underlying causes of Acute Ocular Pain) are more common among females as compared to males.
Acute Ocular Pain Market Trends Analysis
The Acute Ocular Pain market size is expected to increase during the forecast period owing to the increase in the incidence of Acute Ocular Pain in the 7MM and the expected launch of emerging therapies.
The Acute Ocular Pain market analysis section of the report helps to understand the current and forecasted Acute Ocular Pain market trends by analyzing the impact of current therapies on the market, unmet needs, drivers, and barriers.
The report gives complete detail of Acute Ocular Pain market size and shares of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, and view of the key opinion leaders.
Acute Ocular Pain Therapeutics Market
Acute Ocular Pain is typically treated with topical steroids, topical NSAID, systemic NSAID, lubricant ointment, gel or drops, bandage contact lens, or a few doses of oral opiate or topical anesthetic.
Pain management and treatment options usually depend on the underlying condition. Topical agents target the anterior structures of the eye with minimal systemic absorption. They are frequently prescribed in addition to oral peripheral-acting agents such as acetaminophen or centrally-acting opioid analgesics such as hydrocodone.
To redress the current issues, only a few companies are currently working toward this indication to meet the needs of the market. Pipeline drugs in clinical development are designed to address the major unmet needs in Acute Ocular Pain treatment. The other factors that shall further expedite the growth of the Acute Ocular Pain market include increasing awareness about available treatments during the forecast period.
Acute Ocular Pain Epidemiology Forecast
The Acute Ocular Pain epidemiology section covers insights about historical and current Acute Ocular Pain patient pool and forecasted trends for every seven major countries (i.e., the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
It helps to recognize the causes of current and forecasted Acute Ocular Pain Epidemiology trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool and their trends, along with assumptions undertaken.
Acute Ocular Pain Epidemiology Segmentation -
- Total Incidence of Acute Ocular Pain
- Incidence of Acute Ocular Pain by Underlying Causes
- Treatable Cases of Acute Ocular Pain
The current emerging pipeline of Acute Ocular Pain is weak as most of the pipeline products are not in higher phases of the clinical trial. The current unmet need for safe and effective therapies for long-term use offers a great opportunity for the development of novel therapies.
- Pharmaleads SA/IACTA
- SiteOne Therapeutics
Acute Ocular Pain Therapies Covered in the report include PL265 (DENKI), NaV1.7 inhibitors, and many more.
For more details, visit: Acute Ocular Pain Market Trends